Company: SWKH
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001628280-25-040420
Chunk: 88

Company: SWK Holdings Corp
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 88
---
 2,285 Pharmaceutical manufacturing, research and development— 1,403 — 1,403 Depreciation and amortization expense— — 38 38 General and administrative expense127 1,296 4,697 6,120 Other expense, net(2,281)(82)— (2,363)Income tax expense— — 2,304 2,304 Net income (loss)17,439 (518)(8,846)8,075 Six Months Ended June 30, 2024Finance ReceivablesPharmaceutical Development and OtherHolding Company and OtherConsolidatedRevenue$21,021 $1,083 $— $22,104 Other revenue103 — — 103 Provision for credit losses9,392 — — 9,392 Loss on impairment of intangible assets— 5,771 — 5,771 Interest expense590 5 1,780 2,375 Pharmaceutical manufacturing, research and development expense— 1,050 — 1,050 Depreciation and amortization expense— 892 43 935 Change in fair value of acquisition-related contingent consideration— (4,900)— (4,900)General and administrative expense169 1,457 3,978 5,604 Other income (expense), net3,843 — (411)3,432 Income tax expense— — 1,264 1,264 Net income (loss)14,816 (3,192)(7,476)4,148 Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and non-MOD3 corporate employees, which have been included for purposes of reconciling to the consolidated amounts. The following table presents total assets for the Company's reportable segments for the periods indicated (in thousands):June 30, 2025December 31, 2024Total AssetsFinance receivables$253,459 $299,248 Pharmaceutical development and other8,976 7,786 Holdings Company and other23,262 25,201 Total$285,697 $332,235 

25

ITEM 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF